Ultrahuman Healthcare Pvt. Ltd.

Ultrahuman Healthcare Pvt. Ltd.

Ultrahuman Healthcare Pvt. Ltd. was founded in 2019, per public record, by Mohit Kumar and Vatsal Singhal as a health technology firm focused on metabolic optimization. The company's flagship product, Ultrahuman M1, is a continuous glucose monitor (CGM) that uses a biosensor worn on the arm, paired with a mobile app that analyzes glucose responses to meals, exercise, and sleep. It is structured as a venture-backed private company, raising over $25 million in Series A and Series B funding from investors including Blume Ventures, Alpha Wave Global, and Steadview Capital. The firm's strategy centers on direct-to-consumer sales and corporate wellness partnerships, with a subscription model for the sensor and app service. It competes in the wearables and digital health space against firms like Levels, Nutrisense, and Supersapiens. Geographic footprint includes India, the United States, the United Kingdom, and several Middle Eastern markets. Confirmed investors include Blume Ventures (per Crunchbase, 2020) and Alpha Wave Global (per the firm's press releases, 2022). Ultrahuman reported over 100,000 users by early 2025 (per the firm's official blog, February 2025). The team size is estimated at 200–300 professionals across engineering, data science, and sales functions based on public LinkedIn estimates. The company launched a version for athletes, Ultrahuman M1 Pro, in 2024. It maintains an R&D office in Bengaluru and a small commercial team in San Francisco. The structural differentiator is its hardware-enabled subscription model, which generates recurring revenue from consumable sensors and app subscriptions, unlike pure-play software health apps. This model creates a data flywheel: each user generates longitudinal glucose data that improves the AI's predictive accuracy for the broader user base. It does not manage external capital or operate as a fund.